These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36183444)

  • 1. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.
    Carlsson G; Koumarianou A; Guren TK; Haux J; Katsaounis P; Kentepozidis N; Pfeiffer P; Brændengen M; Mavroudis D; Taflin H; Skintemo L; Tell R; Papadimitriou C
    ESMO Open; 2022 Oct; 7(5):100589. PubMed ID: 36183444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.
    Tabernero J; Yoshino T; Stintzing S; de Gramont A; Gibbs P; Jonker DJ; Nygren P; Papadimitriou C; Prager GW; Tell R; Lenz HJ
    Cancer Res Commun; 2024 Jan; 4(1):28-37. PubMed ID: 38059497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
    Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
    Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
    Glimelius B; Stintzing S; Marshall J; Yoshino T; de Gramont A
    Cancer Treat Rev; 2021 Jul; 98():102218. PubMed ID: 34015686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
    Taflin H; Odin E; Carlsson G; Tell R; Gustavsson B; Wettergren Y
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):31-41. PubMed ID: 33099678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.
    Denda T; Kanda M; Morita Y; Kim HM; Kashiwada T; Matsuda C; Fujieda S; Nakata K; Murotani K; Oba K; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1253-1261. PubMed ID: 27807652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
    Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
    Ohta T; Kato T; Kawakami H; Miyake Y; Goto M; Iwamoto S; Otsuji T; Nakamura M; Sugimoto N; Okamura S; Kotaka M; Tsujie M; Tokunaga Y; Mishima H; Hata T; Shimokawa T; Kurokawa Y; Satoh T
    Int J Clin Oncol; 2020 Jul; 25(7):1291-1298. PubMed ID: 32219630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
    van de Vlasakker VCJ; Guchelaar NAD; van den Heuvel TBM; Lurvink RJ; van Meerten E; Bax RJF; Creemers GM; van Hellemond IEG; Brandt-Kerkhof ARM; Madsen EVE; Nederend J; Koolen SLW; Nienhuijs SW; Kranenburg O; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA; ;
    BMJ Open; 2024 Jan; 14(1):e077667. PubMed ID: 38238055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
    BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
    Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
    Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
    Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
    Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.